Despite the absence of the CD20 receptor on neutrophils, neutropenia remains an uncommon but important adverse event associated with both rituximab and ocrelizumab, with incidence rates reported at 4.5–6.5% for rituximab and 1% for ocrelizumab, respectively (28, 29). This evidence concerns the gene MS4A1 and neutropenia.